FAIM
NBSE

Financial Advocates Investment Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Financial Advocates Investment Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-500
Closed -$72K – 549
2019
Q4 		$72K Buy
+500
New +$58.6K 0.01% 503

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PPCM
Pillar Pacific Capital Management Pacifica, California $1.29B AUM 80.18% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Financial Advocates Investment Management's NBSE Position: Q1 2020 in Review

Financial Advocates Investment Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2020, closing a stake of 500 shares — an estimated $72K sold.

Financial Advocates Investment Management first reported a position in NBSE in Q4 2019 and held it in 1 quarter. The position peaked at $72K in Q4 2019. 25 funds tracked by Wall St. Rank hold NBSE as of Q1 2020.

  • Financial Advocates Investment Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Financial Advocates Investment Management sold 500 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $72K.
  • Financial Advocates Investment Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Financial Advocates Investment Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $72K in Q4 2019.
  • 25 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Financial Advocates Investment Management's 13F filing for Q1 2020, filed 29 Apr 2020.